Novartis Shakes Up Executive Suite with Appointments and Transitions
The president of Novartis (NYSE: NVS)’ International Business Unit has this week declared a series...
NYSE: NVS
Novartis Inks Deal to Acquire Mariana Oncology, Bolstering Radioligand Therapy Portfolio
Swiss pharmaceutical giant Novartis (NYSE: NVS) is poised to expand its oncology portfolio by acquiring...
Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...
Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Novartis’s Lutathera Secures FDA Approval for Pediatric Gastroenteropancreatic NETs
The US Food and Drug Administration (FDA) has granted regulatory approval to Novartis (NYSE: NVS)...
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...
Novartis’s Kesimpta Shows Sustained Efficacy in 6-Year Relapsing MS Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) has this week unveiled six-year efficacy data for its...
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...
Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value
Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...
Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...
Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case
Sandoz (SIX: SDZ), the Swiss-based pharmaceutical company, announced this week that its U.S. subsidiaries have...
Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration
Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO:...
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...